Views & Analysis | Perspectives on pharma industry issues

Oncology

pharmaphorum podcast Episode 282 at ESMO26: Dr Chuck Link, Syncromune

ESMO26: Lowering toxicity, extending lives, with Syncromune

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Oncology

Why precision biomarkers will change the future of breast ca...

Blood-based biomarkers can provide an earlier, dynamic view of what is happening inside a patient, creating an opportunity to detect changes sooner.

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Oncology

Sponsored

12 Questions with Julia Jakl

Learn more about Julia Jakl, VP and Business Unit Head, Oncology UK at GSK, in a new 12 Questions With.

Market Access

Sponsored

The pre-commercial case for connecting data before acquiring...

For EBPs, launch requires a data strategy that starts with agreement on the KPIs, and those depend on the therapeutic areas.

Articles

Editor’s voice: January – audience reach and feedback

pharmaphorum’s Managing Editor, Rebecca Aris, shares some of the feedback we’ve received on our content over the last month. Every day we engage with our audience, through Twitter, Facebook, LinkedIn, the list goes on...

Articles

Personalized change

Nathan Nagel discusses the change in approach to drug development following the increase in personalized medicine. The purpose of this article is to provoke thoughts about how the new paradigm of personalized medicine may...

Articles

Data transparency in clinical trials

Trish Groves of the BMJ offers an overview of the latest news on data transparency in clinical trials. Why should patient level data from clinical trials be shared? The best reasons for data sharing are to optimise the evidence base...

Sales & Marketing

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Sales & Marketing

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Digital

Sponsored

Why AI transformation is really about people

Jeff Kaminski, global head of AI and data at Axtria and a former industry analyst, discusses culture, governance, and leadership challenges around AI.

Digital